首页> 美国卫生研究院文献>PLoS Clinical Trials >Cancer Screening by Systemic Administration of a Gene Delivery Vector Encoding Tumor-Selective Secretable Biomarker Expression
【2h】

Cancer Screening by Systemic Administration of a Gene Delivery Vector Encoding Tumor-Selective Secretable Biomarker Expression

机译:通过全身给药编码肿瘤选择性分泌生物标志物表达的基因传递载体进行癌症筛查。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cancer biomarkers facilitate screening and early detection but are known for only a few cancer types. We demonstrated the principle of inducing tumors to secrete a serum biomarker using a systemically administered gene delivery vector that targets tumors for selective expression of an engineered cassette. We exploited tumor-selective replication of a conditionally replicative Herpes simplex virus (HSV) combined with a replication-dependent late viral promoter to achieve tumor-selective biomarker expression as an example gene delivery vector. Virus replication, cytotoxicity and biomarker production were low in quiescent normal human foreskin keratinocytes and high in cancer cells in vitro. Following intravenous injection of virus >90% of tumor-bearing mice exhibited higher levels of biomarker than non-tumor-bearing mice and upon necropsy, we detected virus exclusively in tumors. Our strategy of forcing tumors to secrete a serum biomarker could be useful for cancer screening in high-risk patients, and possibly for monitoring response to therapy. In addition, because oncolytic vectors for tumor specific gene delivery are cytotoxic, they may supplement our screening strategy as a “theragnostic” agent. The cancer screening approach presented in this work introduces a paradigm shift in the utility of gene delivery which we foresee being improved by alternative vectors targeting gene delivery and expression to tumors. Refining this approach will usher a new era for clinical cancer screening that may be implemented in the developed and undeveloped world.
机译:癌症生物标志物有助于筛查和早期发现,但仅针对几种癌症类型而闻名。我们证明了使用靶向肿瘤以选择性表达工程化表达盒的全身给药基因递送载体诱导肿瘤分泌血清生物标志物的原理。我们利用条件复制性单纯疱疹病毒(HSV)与复制依赖性晚期病毒启动子结合的肿瘤选择性复制来实现肿瘤选择性生物标记物表达,作为示例基因传递载体。在静态的正常人包皮角质形成细胞中,病毒复制,细胞毒性和生物标志物的产生较低,而在体外癌细胞中则较高。静脉注射病毒后,> 90%的荷瘤小鼠比非荷瘤小鼠表现出更高水平的生物标志物,尸检后,我们仅在肿瘤中检测到病毒。我们强迫肿瘤分泌血清生物标志物的策略可能对高危患者的癌症筛查有用,并可能用于监测对治疗的反应。此外,由于用于肿瘤特异性基因递送的溶瘤载体具有细胞毒性,因此它们可以作为“促尿激素”药物补充我们的筛选策略。这项工作中提出的癌症筛查方法在基因传递的实用性方面引入了范式转变,我们预见到,通过靶向基因传递和向肿瘤表达的替代载体,这种转移将得到改善。完善这种方法将为临床癌症筛查开创一个新时代,该时代可能会在发达国家和不发达国家实施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号